Q1 Earnings Estimate for Cresco Labs Issued By Roth Capital

Cresco Labs Inc. (OTCMKTS:CRLBF) – Equities researchers at Roth Capital issued their Q1 2025 EPS estimates for Cresco Labs in a research note issued to investors on Thursday, March 13th. Roth Capital analyst W. Kirk expects that the company will earn ($0.03) per share for the quarter. The consensus estimate for Cresco Labs’ current full-year earnings is ($0.20) per share. Roth Capital also issued estimates for Cresco Labs’ Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.08) EPS and FY2026 earnings at ($0.04) EPS.

Several other analysts have also recently issued reports on CRLBF. Cormark raised shares of Cresco Labs from a “hold” rating to a “moderate buy” rating in a research note on Monday. Atb Cap Markets cut shares of Cresco Labs from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 9th. Two research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $3.00.

Cresco Labs Stock Down 4.0 %

Shares of OTCMKTS CRLBF opened at $0.71 on Monday. Cresco Labs has a 12-month low of $0.70 and a 12-month high of $2.60. The stock has a market cap of $344.14 million, a PE ratio of -3.53 and a beta of 1.79. The company has a current ratio of 1.97, a quick ratio of 1.39 and a debt-to-equity ratio of 1.80. The company has a 50-day moving average of $0.88 and a 200 day moving average of $1.19.

Cresco Labs (OTCMKTS:CRLBF) last released its quarterly earnings results on Friday, March 14th. The company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01). Cresco Labs had a negative net margin of 9.15% and a negative return on equity of 16.52%. The firm had revenue of $176.00 million during the quarter, compared to the consensus estimate of $172.10 million.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.